Analyst Price Targets — INNV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 8, 2023 8:02 am | — | J.P. Morgan | $8.00 | $7.50 | Benzinga | JP Morgan Maintains Neutral on InnovAge Holding, Raises Price Target to $8 |
| November 23, 2022 9:34 am | — | Goldman Sachs | $8.00 | $6.80 | Benzinga | Goldman Sachs Maintains Neutral on InnovAge Holding, Raises Price Target to $8 |
| November 16, 2022 7:53 am | — | Citigroup | $8.00 | $7.25 | Benzinga | Citigroup Maintains Neutral on InnovAge Holding, Raises Price Target to $8 |
| September 15, 2022 7:13 am | — | Barclays | $5.00 | $4.94 | Benzinga | Barclays Maintains Equal-Weight on InnovAge Holding, Lowers Price Target to $5 |
| April 20, 2022 6:08 am | — | Piper Sandler | $5.00 | $6.59 | Benzinga | Piper Sandler Downgrades InnovAge Holding to Underweight, Raises Price Target to $5 |
Latest News for INNV
DENVER, May 12, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced that Jennifer Browne has been appointed President and Chief Operating Officer, effective June 8, 2026. Ms. Browne…
InnovAge Holding Corp. (INNV) Q3 2026 Earnings Call Transcript
InnovAge Holding Corp. (INNV) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of $0.06. This compares to a loss of $0.08 per share a year ago.
DENVER, May 05, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal third quarter ended March 31, 2026. We delivered a solid third quarter, reflecting…
InnovAge heads into fiscal Q3 earnings with strong growth momentum and margin gains, but seasonal cost pressures and fading Medicaid tailwinds may temper near-term upside.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INNV.
U.S. House Trading
No House trades found for INNV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.